A Pilot Study for the Improvement of Cognitive Function (ADAS-Cog 13) After Transcranial Direct Current Stimulation in Mild Cognitive Impairment
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Mild Cognitive Impairment
- Sponsor
- Samsung Medical Center
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Change in Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 13)
- Last Updated
- 11 years ago
Overview
Brief Summary
The primary objective of this preliminary study is to investigate whether the transcranial direct current stimulation (tDCS) improves the cognitive function in patients with Mild Cognitive Impairment (MCI)
Detailed Description
Twenty patients were recruited and randomized to receive either real or sham-tDCS over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC). Patients or their legally responsible caregivers were provided with mobile tDCS device, and were instructed to use it at home. 30-minute session of the stimulation were applied everyday in the morning for 12 weeks. The patients were evaluated at baseline, at week 6 and 12.
Investigators
Duk Lyul Na
Professor of Neurology, Sungkyunkwan University School of Medicine
Samsung Medical Center
Eligibility Criteria
Inclusion Criteria
- •Subjects who have a subjective memory impairment
- •Subjects who have Korean version of Mini Mental Status Examination score 24 or more
- •Subjects who have SVLT and RCFT delayed recall test scores lower than 1.5SD
- •Subjects who have had other cognitive impairments besides memory
- •Subjects with late amnestic mild cognitive impairment, verbal and visual memory impairment and multiple domain problem
- •Subjects who have Seoul-Instrumental Activities of Daily Living score (S-IADL) of 8 or lower
- •Subjects who are right-handed
- •Subjects who are able to read and write
- •Both subject and legally responsible caregiver have provided informed consent
- •According to the latest MRI result, periventricular white matter cap or band is less than 10mm, or the deep white matter hyper-intensity is less than 25 mm
Exclusion Criteria
- •Subjects who have a history of stroke and seizures
- •Subjects who have any illnesses that may disturb the patients completing the trials, including stroke, Parkinson's disease, type 1 diabetes, uncontrollable high blood pressure, Huntington's disease, cerebral palsy, liver failure, nephritis, encephalitis, meningitis, scleroma, seizures and a transient ischemic attack.
- •Subjects who have neurologic problems on physical examination that cause memory disturbances
- •Subjects who have a history of DSM-IV Axis I disorders
- •Subjects who have extremely sensitive skin
- •Subjects who have suffered from the cancer in 3 years
- •Subjects who have had a cerebrovascular neurosurgery in medical history
- •Subjects who have dyspnea in sitting position
- •Subjects who have problems with memory, language and problem-solving for 2 hours after the heart attack.
- •Subjects who have a history of drug or alcohol abuse (in the past 5 years)
Outcomes
Primary Outcomes
Change in Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog 13)
Time Frame: from baseline to Week 6 and Week 12
Secondary Outcomes
- Change in questionnaire(from baseline to Week 12)
- Change in Clinician's Interview-Based Impression of Change Plus (CIBIC plus)(from baseline to Week 12)
- Change in tDCS feedback(Week 2, 4, 6 and 12)
- Change in activities of daily living(from baseline to Week 12)
- Change in Korean version of Geriatric Depression Scale (K-GDS)(from baseline to Week 6 and Week 12)
- Change in cognitive function(from baseline to Week 6 and Week 12)
- Change in Multifactorial Memory Questionnaire (MMQ)(from baseline to Week 6 and Week 12)